CJC-1295 vs Ipamorelin

CJC-1295 and ipamorelin are growth hormone (GH) secretagogues used individually and in combination for GH deficiency and anti-aging protocols. CJC-1295 is a GHRH analog producing sustained GH elevation, while ipamorelin is a selective GHSR1a agonist producing pulsatile GH release. Their distinct pharmacokinetic profiles require different dosing strategies, and their combination produces synergistic GH release.

Single-Agent Dosing

CJC-1295 Dosing

Formulation	Half-Life	Typical Dose	Frequency	Route
CJC-1295-DAC	6–8 days	30 µg/kg	1–2× per week	SC
CJC-1295 no-DAC	30–40 min	30–60 µg/kg	1–3× per day	SC

CJC-1295-DAC Protocol:

Week	Dose	Frequency	Assessment
1–2	15 µg/kg	1× per week	Tolerability
3–4	30 µg/kg	1× per week	GH/IGF-1 check
5+	30–60 µg/kg	1–2× per week	Titrate to IGF-1 target

CJC-1295 no-DAC Protocol:

Week	Dose	Frequency	Timing
1–2	30 µg/kg	2× per day	Morning, evening
3–4	30 µg/kg	3× per day	Pre-meal
5+	30–60 µg/kg	3× per day	Pre-meal

Ipamorelin Dosing

Dose	Half-Life	Frequency	Route	Expected GH Pulse
100 µg	~2 hours	1–2× daily	SC	10–15 ng/mL
200 µg	~2 hours	2–3× daily	SC	15–25 ng/mL
300 µg	~2 hours	2–3× daily	SC	20–30 ng/mL

Ipamorelin Protocol:

Week	Dose	Frequency	Timing
1–2	100 µg	2× daily	Morning, evening
3–4	200 µg	2× daily	Pre-meal
5+	200–300 µg	3× daily	Pre-meal

Combination Dosing Protocols

Standard Combination Protocol

Agent	Dose	Frequency	Timing
CJC-1295-DAC	30 µg/kg	2× per week	Morning (Mon/Thu)
Ipamorelin	200 µg	2–3× daily	Pre-meal

Advanced Combination Protocol

Phase	CJC-1295-DAC	Ipamorelin	Duration	Assessment
Loading	30 µg/kg 1×/week	100 µg 2×/day	Weeks 1–2	Tolerability
Escalation	30 µg/kg 2×/week	200 µg 2×/day	Weeks 3–4	GH/IGF-1
Maintenance	30–60 µg/kg 2×/week	200–300 µg 3×/day	Weeks 5+	IGF-1 target

Dose-Escalation Schedule

Week	CJC-1295-DAC	Ipamorelin	Expected GH	Expected IGF-1
1	30 µg/kg 1×/week	100 µg 2×/day	15–25 ng/mL	Baseline +10%
2	30 µg/kg 1×/week	150 µg 2×/day	20–30 ng/mL	Baseline +15%
3	30 µg/kg 2×/week	200 µg 2×/day	25–40 ng/mL	Baseline +25%
4	30 µg/kg 2×/week	200 µg 3×/day	30–50 ng/mL	Baseline +35%
5+	30–60 µg/kg 2×/week	200–300 µg 3×/day	40–60 ng/mL	Baseline +50–100%

Pharmacokinetic Dosing Rationale

CJC-1295: Sustained Elevation

Parameter	CJC-1295-DAC	CJC-1295 no-DAC
Half-life	6–8 days	30–40 min
Dosing rationale	Accumulation → steady state	Pulsatile mimicry
Steady state	4–5 days	Immediate
Missed dose impact	Low (long t½)	High (short t½)
Titration interval	Weekly	Daily

Ipamorelin: Pulsatile Release

Parameter	Ipamorelin
Half-life	~2 hours
Pulse frequency	6–8 per 24 hours
Pulse amplitude	15–25 ng/mL
Trough	Return to baseline between pulses
Dosing rationale	Mimic physiological GH pulsatility

Monitoring Parameters

Baseline Assessment

Test	Purpose	Timing
IGF-1	Baseline GH axis function	Pre-treatment
GH (fasting)	Baseline GH secretion	Pre-treatment
HbA1c	Metabolic baseline	Pre-treatment
Lipid panel	Metabolic baseline	Pre-treatment
CBC	Safety baseline	Pre-treatment
CMP	Liver/renal function	Pre-treatment
PSA (males)	Prostate baseline	Pre-treatment
Thyroid function	Thyroid baseline	Pre-treatment

On-Treatment Monitoring

Test	Frequency	Target
IGF-1	Every 4–6 weeks (initial), then every 3 months	Age-appropriate range
GH (fasting)	Every 3 months	5–15 ng/mL
HbA1c	Every 3 months	Improvement
Lipid panel	Every 6 months	Improvement
CBC	Every 6 months	Stable
CMP	Every 6 months	Stable

IGF-1 Target Ranges

Age Group	IGF-1 Target	Action if Above
25–40 years	200–350 ng/mL	Reduce dose
41–55 years	150–300 ng/mL	Reduce dose
56–70 years	100–250 ng/mL	Reduce dose
>70 years	80–200 ng/mL	Reduce dose

Dose Adjustment Guidelines

IGF-1-Based Titration

IGF-1 Level	Action
Below age-appropriate range	Increase CJC-1295 by 25%
Within range	Maintain current dose
10–20% above range	Reduce CJC-1295 by 25%
>20% above range	Reduce CJC-1295 by 50% or hold

Side Effect-Based Adjustment

Side Effect	Agent	Action
Injection site reaction	Either	Rotate sites, reduce volume
Headache	CJC-1295	Reduce dose, separate from ipamorelin
Facial flushing	CJC-1295	Reduce dose
Joint pain	Either	Reduce dose
Water retention	CJC-1295	Reduce dose
Fatigue	Ipamorelin	Reduce dose, adjust timing

Cycling Protocols

On-Cycle / Off-Cycle

Phase	Duration	Agents	Purpose
On-cycle	8–12 weeks	CJC-1295 + Ipamorelin	GH stimulation
Off-cycle	4–6 weeks	None	Receptor resensitization

Pulsatile Cycling

Phase	Duration	Agents	Purpose
Daily pulsing	Daily	Ipamorelin 3×/day	Mimic physiological pulsatility
Continuous	Continuous	CJC-1295-DAC 2×/week	Sustained GH pool
Integration	Continuous	Both	Sustained + pulsatile

Special Populations

Age Group	CJC-1295-DAC	Ipamorelin	Notes
25–40	30 µg/kg 2×/week	200 µg 2×/day	Standard protocol
41–55	30 µg/kg 2×/week	200 µg 2×/day	Standard protocol
56–70	15–30 µg/kg 2×/week	100–200 µg 2×/day	Start lower
>70	15 µg/kg 2×/week	100 µg 2×/day	Conservative approach

Body Weight-Based Dosing

Body Weight	CJC-1295-DAC (30 µg/kg)	Ipamorelin (fixed)
60 kg	1.8 mg	200 µg
80 kg	2.4 mg	200 µg
100 kg	3.0 mg	200–300 µg
120 kg	3.6 mg	300 µg

Protocol Optimization

Timing Optimization

Agent	Optimal Timing	Rationale
CJC-1295-DAC	Morning (fasting)	Mimics physiological GH release
Ipamorelin	Pre-meal (fasting)	Enhances pulse amplitude
Combination	Separate by ≥2 hours	Avoid competition

Administration Tips

Tip	Rationale
Inject SC (abdomen or thigh)	Optimal absorption
Rotate injection sites	Prevent lipodystrophy
Reconstitute with bacteriostatic water	Sterility
Store reconstituted peptide at 2–8°C	Stability
Use within 30 days of reconstitution	Potency

Summary

CJC-1295 and ipamorelin require distinct dosing strategies due to their different pharmacokinetic profiles. CJC-1295-DAC provides sustained GH elevation with once- or twice-weekly dosing, while ipamorelin produces pulsatile GH release with 2–3 daily injections. Their combination leverages complementary mechanisms for synergistic GH release. Monitoring should include regular IGF-1 assessment with dose titration to age-appropriate ranges. Cycling protocols may prevent receptor desensitization.